We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Milestone Pharmaceuticals’ investigational nasal spray etripamil claimed a phase 3 win, with topline data indicating that abnormal heart rhythms normalized in 64 percent of patients with paroxysmal supraventricular tachycardia (PSVT) compared to 31 percent who used a placebo spray. Read More
GSK has unveiled impressive numbers for its respiratory syncytial virus (RSV) vaccine, touting an overall efficacy rate of more than 94 percent against severe disease in people age 60 years and older. Read More
AstraZeneca is teaming up with DNA sequencing giant Illumina to seek out potential new drug targets using Illumina’s genomic analysis artificial intelligence (AI) technology. Read More
Boston, Mass-based Albireo Pharma said it has hit a phase 3 bull’s eye with Bylvay, an ileal bile acid transport inhibitor under investigation for the treatment of a rare pediatric liver disease called Alagille syndrome. Read More
Sotatercept, Merck’s investigational activin receptor type IIA-Fc (ActRIIA-Fc) fusion protein, has scored a phase 3 win, improving physical function and cardiopulmonary outcomes in people with pulmonary arterial hypertension (PAH). Read More
TauRx Pharmaceuticals is claiming an Alzheimer’s win despite admitting that the study’s placebo blinding broke — and that a valid placebo-controlled trial is impossible with the drug, hydromethylthionine mesylate (HMTM). Read More
Despite failing to achieve both its primary and secondary phase 2 endpoints, an investigational oral solution of gold nanocrystals will go forward into open-label extension studies after a subanalysis found a strong survival benefit in the 30 mg dosing group. Read More
Zealand Pharma’s investigational glucagon-like peptide (GLP)-2 analog glepaglutide hit its primary phase 3 endpoint of reducing parenteral nutrition volume in patients with short bowel syndrome, but only when given twice a week. Read More